Hsp70 inhibitors: Implications for the treatment of colorectal cancer

被引:37
|
作者
Moradi-Marjaneh, Reyhaneh [1 ]
Paseban, Maryam [2 ]
Marjaneh, Mahdi Moradi [3 ]
机构
[1] Torbat Heydariyeh Univ Med Sci, Torbat Heydariyeh, Iran
[2] Mashhad Univ Med Sci, Sch Med, Dept Physiol, Mashhad, Razavi Khorasan, Iran
[3] QIMR Berghofer Med Res Inst, Canc Div, Brisbane, Qld, Australia
关键词
cancer; colorectal; Hsp70; inhibitor; SMALL-MOLECULE INHIBITOR; ADENOSINE-DERIVED INHIBITORS; COLON-CARCINOMA CELLS; HEAT-SHOCK PROTEINS; HEAT-SHOCK-PROTEIN-70; HSP70; METHYLENE-BLUE; ANTICANCER ACTIVITY; INDUCED APOPTOSIS; OXIDATIVE INJURY; CYTOSOLIC HSP70;
D O I
10.1002/iub.2157
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer (CRC) is one of the most common malignancies in the world. Despite intensive advances in diagnosis and treatment of CRC, it is yet one of the leading cause of cancer related morbidity and mortality. Therefore, there is an urgent medical need for alternative therapeutic approaches to treat CRC. The 70 kDa heat shock proteins (Hsp70s) are a family of evolutionary conserved heat shock proteins, which play an important role in cell homeostasis and survival. They overexpress in various types of malignancy including CRC and are typically accompanied with poor prognosis. Hence, inhibition of Hsp70 may be considered as a striking chemotherapeutic avenue. This review summarizes the current knowledge on the progress made so far to discover compounds, which target the Hsp70 family, with particular emphasis on their efficacy in treatment of CRC. We also briefly explain the induction of Hsp70 as a strategy to prevent CRC.
引用
收藏
页码:1834 / 1845
页数:12
相关论文
共 50 条
  • [1] Prognostic Significance of the Hsp70 Gene Family in Colorectal Cancer
    Jiang, Wenjun
    Pan, Xiaohang
    Yan, Haifan
    Wang, Guoping
    MEDICAL SCIENCE MONITOR, 2021, 27
  • [2] Functional Analysis of Hsp70 Inhibitors
    Schlecht, Rainer
    Scholz, Sebastian R.
    Dahmen, Heike
    Wegener, Ansgar
    Sirrenberg, Christian
    Musil, Djordje
    Bomke, Joerg
    Eggenweiler, Hans-Michael
    Mayer, Matthias P.
    Bukau, Bernd
    PLOS ONE, 2013, 8 (11):
  • [3] Cotargeting autophagy and hsp70 for breast cancer treatment
    Jiang, Xiao-xiao
    Yong, Bao
    Yang, Yong-hua
    ACTA PHARMACOLOGICA SINICA, 2013, 34 : 7 - 8
  • [4] The HSP70 family and cancer
    Murphy, Maureen E.
    CARCINOGENESIS, 2013, 34 (06) : 1181 - 1188
  • [5] Design and optimization of a new series of HSP70 inhibitors for use in the treatment of pancreatic cancer.
    Maxwell, David S.
    Sun, Duoli
    Peng, Zhenghong
    Qi, Wei
    McConkey, David
    Abbruzzese, James L.
    Bornmann, William G.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [6] Hsp70 interactomics in cancer science
    Shiota, Masayuki
    Tanaka, Masako
    Iwao, Hiroshi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 : 18P - 18P
  • [7] Hsp70 in cancer: back to the future
    Sherman, M. Y.
    Gabai, V. L.
    ONCOGENE, 2015, 34 (32) : 4153 - 4161
  • [8] Hsp70 in cancer: back to the future
    M Y Sherman
    V L Gabai
    Oncogene, 2015, 34 : 4153 - 4161
  • [9] Targeting HSP70 for Cancer Therapy
    Galluzzi, Lorenzo
    Giordanetto, Fabrizio
    Kroemer, Guido
    MOLECULAR CELL, 2009, 36 (02) : 176 - 177
  • [10] HSP70 Is Required for Loss of Heterozygosity in the ApcMin/ plus Model of Colorectal Cancer
    Tao, Yun
    Messer, Jeannette S.
    Goss, Kathleen H.
    Hart, John
    Bissonnette, Marc
    Chang, Eugene B.
    GASTROENTEROLOGY, 2014, 146 (05) : S151 - S152